TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 5:32 · $CRISPR · Why AI Hasn't Cured Anything...Yet, According to Jennifer Doudna | The Circuit
episode briefing
Bloomberg Originals

Why AI Hasn't Cured Anything...Yet, According to Jennifer Doudna | The Circuit

2026-06-24 · 3 company · 0 thematic
sentiment
2 bull1 bear0 neu
speakers
jennifer doudna

Biochemist and Nobel laureate, awarded the 2020 Nobel Prize in Chemistry for co-developing CRISPR gene editing.

quote
“I think we've now spun out 31 companies at last count, $9 billion valuation. If you add it all up, over 2,500 jobs created largely here in California.”
—jennifer doudna
now playing · $CRISPR
$CRISPR···bullish· mediumjennifer doudna
Doudna says the CRISPR startup ecosystem has already spun out 31 companies worth $9B
The investment signal is not a single ticker but the scale of the CRISPR commercialization pipeline: dozens of companies, thousands of jobs, and continued progress toward real-wor…
$OPENAIbearish· mediumjennifer doudna
Jennifer Doudna pushes back on OpenAI-style claims that chatbots will own drug discovery
Doudna says AI can help summarize data and improve discovery efficiency, but she does not see chatbots inventing new drug ideas or justifying a claim on future drug sales today.
$CRISPR···bullish· mediumjennifer doudna
Doudna says in-vivo delivery is the next unlock for CRISPR therapies
Doudna identifies delivery into the patient's body as a core bottleneck and the next development path for turning CRISPR from ex-vivo procedures into broader therapeutics.